| Ident. | Authors (with country if any) | Title |
|---|
| 000160 (2021) |
Saeidreza Jamalimoghadamsiahkali [Iran] ; Besharat Zarezade [Iran] ; Sogol Koolaji [Iran] ; Seyedahmad Seyedalinaghi [Iran] ; Abolfazl Zendehdel [Iran] ; Mohammad Tabarestani [Iran] ; Ehsan Sekhavati Moghadam [Iran] ; Ladan Abbasian [Iran] ; Seyed Ali Dehghan Manshadi [Iran] ; Mohamadreza Salehi [Iran] ; Malihe Hasannezhad [Iran] ; Sara Ghaderkhani [Iran] ; Mohsen Meidani [Iran] ; Faeze Salahshour [Iran] ; Fatemeh Jafari [Iran] ; Navid Manafi [Canada] ; Fereshteh Ghiasvand [Iran] | Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. |
| 000195 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000218 (2021) |
Marcelo Rodrigues Dos Santos [Brésil] | Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. |
| 000230 (2021) |
Faryal Khamis [Oman] ; Hanan Al Naabi [Oman] ; Adil Al Lawati [Oman] ; Zaiyana Ambusaidi [Oman] ; Mariam Al Sharji [Oman] ; Umkulthum Al Barwani [Oman] ; Nenad Pandak [Oman] ; Zakariya Al Balushi [Oman] ; Maher Al Bahrani [Oman] ; Issa Al Salmi [Oman] ; Ibrahim Al-Zakwani [Oman] | Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. |
| 000267 (2021) |
Raymond Chee Seong Seet [Singapour] ; Amy May Lin Quek [Singapour] ; Delicia Shu Qin Ooi [Singapour] ; Sharmila Sengupta [Singapour] ; Satish Ramapatna Lakshminarasappa [Singapour] ; Chieh Yang Koo [Singapour] ; Jimmy Bok Yan So [Singapour] ; Boon Cher Goh [Singapour] ; Kwok Seng Loh [Singapour] ; Dale Fisher [Singapour] ; Hock Luen Teoh [Singapour] ; Jie Sun [Singapour] ; Alex R. Cook [Singapour] ; Paul Anantharajah Tambyah [Singapour] ; Mikael Hartman [Singapour] | Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. |
| 000356 (2021) |
Mohamed O. Saad [Qatar] | Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000448 (2021) |
Philippe Gautret [France] ; Jean-Christophe Lagier [France] ; Stéphane Honoré [France] ; Van Thuan Hoang [Viêt Nam] ; Philippe Colson [France] ; Didier Raoult [France] | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. |
| 000479 (2021) |
Carlos Gustavo Wambier [États-Unis] | Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". |
| 000542 (2021) |
Philippe Gautret [France] ; Van Thuan Hoang [Viêt Nam] ; Jean-Christophe Lagier [France] ; Didier Raoult [France] | Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. |
| 000546 (2021) |
Luis Gabriel Parra-Lara [Colombie] ; Juan José Martinez-Arboleda [Colombie] ; Daniel Francisco Isaza-Pierotti [États-Unis] ; Fernando Rosso [Colombie] | Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| 000565 (2021) |
Iwein Gyselinck [Belgique] ; Laurens Liesenborghs [Belgique] ; Ewout Landeloos [Belgique] ; Ann Belmans [Belgique] ; Geert Verbeke [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] ; W. Janssens [Belgique] | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. |
| 000741 (2021) |
Álvaro Réa-Neto [Brésil] ; Rafaella Stradiotto Bernardelli [Brésil] ; Bruna Martins Dzivielevski Câmara [Brésil] ; Fernanda Baeumle Reese [Brésil] ; Marcos Vinicius Oliveira Queiroga [Brésil] ; Mirella Cristine Oliveira [Brésil] | An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. |
| 000757 (2021) |
Michael Ewers [Allemagne] ; John P A. Ioannidis [États-Unis] ; Nikolaus Plesnila [Allemagne] | Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive. |
| 000C42 (2020) |
Ehsan Sekhavati [Iran] ; Fatemeh Jafari [Iran] ; Seyedahmad Seyedalinaghi [Iran] ; Saeidreza Jamalimoghadamsiahkali [Iran] ; Sara Sadr [Iran] ; Mohammad Tabarestani [Iran] ; Mohammad Pirhayati [Iran] ; Abolfazl Zendehdel [Iran] ; Navid Manafi [Iran] ; Mahboubeh Hajiabdolbaghi [Iran] ; Zahra Ahmadinejad [Iran] ; Hamid Emadi Kouchak [Iran] ; Sirous Jafari [Iran] ; Hosein Khalili [Iran] ; Mohamadreza Salehi [Iran] ; Arash Seifi [Iran] ; Fereshteh Shahmari Golestan [Iran] ; Fereshteh Ghiasvand [Iran] | Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. |
| 000D01 (2020) |
Frits R. Rosendaal [Pays-Bas] | Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. |
| 000F09 (2020) |
Patrick Brest [France] ; Jonathan Benzaquen [France] ; Daniel J. Klionsky [États-Unis] ; Paul Hofman [France] ; Baharia Mograbi [France] | Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype? |
| 000F27 (2020) |
Magnus Nakrem Lyngbakken [Norvège] ; Jan-Erik Berdal [Norvège] ; Arne Eskesen [Norvège] ; Dag Kvale [Norvège] ; Inge Christoffer Olsen [Norvège] ; Anbj Rg Rangberg [Norvège] ; Christine Monceyron Jonassen [Norvège] ; Torbj Rn Omland [Norvège] ; Helge R Sj [Norvège] ; Olav Dalgard [Norvège] | Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. |
| 000F98 (2020) |
| Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. |
| 001042 (2020) |
Emanuel Della-Torre [Italie] ; Corrado Campochiaro [Italie] ; Giulio Cavalli [Italie] ; Giacomo De Luca [Italie] ; Angela Napolitano [Italie] ; Salvatore La Marca [Italie] ; Nicola Boffini [Italie] ; Valentina Da Prat [Italie] ; Gaetano Di Terlizzi [Italie] ; Marco Lanzillotta [Italie] ; Patrizia Rovere Querini [Italie] ; Annalisa Ruggeri [Italie] ; Giovanni Landoni [Italie] ; Moreno Tresoldi [Italie] ; Fabio Ciceri [Italie] ; Alberto Zangrillo [Italie] ; Francesco De Cobelli [Italie] ; Lorenzo Dagna [Italie] | Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. |
| 001142 (2020) |
Samuel M. Brown ; Ithan D. Peltan ; Brandon Webb [États-Unis] ; Naresh Kumar ; Nathan Starr [États-Unis] ; Colin Grissom ; Whitney R. Buckel ; Raj Srivastava [États-Unis] ; Estelle S. Harris ; Lindsay M. Leither ; Stacy A. Johnson ; Robert Paine ; Tom Greene [États-Unis] | Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. |
| 001168 (2020) |
Wei Tang [République populaire de Chine] ; Zhujun Cao [République populaire de Chine] ; Mingfeng Han [République populaire de Chine] ; Zhengyan Wang [République populaire de Chine] ; Junwen Chen [République populaire de Chine] ; Wenjin Sun [République populaire de Chine] ; Yaojie Wu [République populaire de Chine] ; Wei Xiao [République populaire de Chine] ; Shengyong Liu [République populaire de Chine] ; Erzhen Chen [République populaire de Chine] ; Wei Chen [République populaire de Chine] ; Xiongbiao Wang [République populaire de Chine] ; Jiuyong Yang [République populaire de Chine] ; Jun Lin [République populaire de Chine] ; Qingxia Zhao [République populaire de Chine] ; Youqin Yan [République populaire de Chine] ; Zhibin Xie [Oman] ; Dan Li [République populaire de Chine] ; Yaofeng Yang [République populaire de Chine] ; Leshan Liu [République populaire de Chine] ; Jieming Qu [République populaire de Chine] ; Guang Ning [République populaire de Chine] ; Guochao Shi [République populaire de Chine] ; Qing Xie [Oman] | Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. |
